Iodometomidate I-123, R-

Iodometomidate I-123, R-

SCHEMBL4870040

COC(=O)c1cncn1C(C)c1ccc(I)cc1

nearest known ligand 0.74

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.74
GABRA1 P14867 7/20 0.56
GABRB2 P47870 6/20 0.56
CYP11B1 P15538 3/20 0.56
CYP11B2 P19099 3/20 0.56
CYP1A2 P05177 2/20 0.56
CYP3A4 P08684 2/20 0.56
LMNA P02545 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
ABCB11 O95342 1/20 0.56
GABRA2 P47869 1/20 0.56
ALDH1A1 P00352 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
GPBAR1 Q8TDU6 4/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
ACACB O00763 1/20 0.34
SLC6A3 Q01959 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iodometomidate I-123, R- SCHEMBL4870043 1.00 MAPK1 (0.74) MAPK1GABRA1GABRB2CYP11B1CYP11B2
SCHEMBL22004285 0.88 MAPK1 (0.76) MAPK1GABRA1GABRB2CYP11B1CYP11B2
Metomidate SCHEMBL491910 0.86 MAPK1 (0.97) MAPK1GABRA1GABRB2CYP11B1CYP11B2
Metomidate SCHEMBL4377172 0.86 MAPK1 (0.97) MAPK1GABRA1GABRB2CYP11B1CYP11B2
Metomidate SCHEMBL1845324 0.85 MAPK1 (1.00) MAPK1GABRA1GABRB2CYP11B1CYP11B2
SCHEMBL16950285 0.85 ALDH1A1 (0.76) MAPK1GABRA1GABRB2CYP11B1CYP11B2
SCHEMBL4865817 0.85 ALDH1A1 (0.76) MAPK1GABRA1GABRB2CYP11B1CYP11B2
SCHEMBL5140230 0.84 MAPK1 (0.70) MAPK1GABRA1GABRB2CYP11B1CYP11B2
SCHEMBL5140228 0.84 MAPK1 (0.70) MAPK1GABRA1GABRB2CYP11B1CYP11B2
SCHEMBL16950273 0.83 GABRA1 (0.56) MAPK1GABRA1GABRB2CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7358369-B2 Radio-halogenated carboxylic ester derivatives of phenylethyl imidazole tomography/scintigraphy imaging for detection of adrenal cortical pathology, e.g. incidentaloma, adenoma, primary and metastatic cortical carcinoma; highly selective with a high rate of accumulation in adrenals; antitumor agents Zolle, Ilse (AT) 2008-04-15 US disclosed
US-7189859-B2 Radiolabelled phenylethyl imidazole carboxylic acid ester derivatives ZOLLE, ILSE (AT) 2007-03-13 US disclosed
US-20070036718-A1 Radio-halogenated carboxylic ester derivatives of phenylethyl imidazole tomography/scintigraphy imaging for detection of adrenal cortical pathology, e.g. incidentaloma, adenoma, primary and metastatic cortical carcinoma; highly selective with a high rate of accumulation in adrenals; antitumor agents ZOLLE, ILSE (AT) 2007-02-15 US disclosed
US-20050033060-A1 Radiolabelled phenylethyl imidazole caboxylic acid ester derivatives ZOLLE, ILSE (AT) 2005-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070036718-A1 Radio-halogenated carboxylic ester derivatives of phenylethyl imidazole tomography/scintigraphy imaging for detection of adrenal cortical pathology, e.g. incidentaloma, adenoma, primary and metastatic cortical carcinoma; highly selective with a high rate of accumulation in adrenals; antitumor agents CDC73, TPD52L2, NTRK1 MAPK1 3794/4885GABRA1 2128/4885GABRB2 3099/4885
US-20050033060-A1 Radiolabelled phenylethyl imidazole caboxylic acid ester derivatives CDC73, BRDT, TEC MAPK1 1940/4885GABRA1 1350/4885GABRB2 2285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.